Type of support |
Approvals 2001-2023 (US$)(17 Sep 2019) |
Commitments 2001-2023 (US$)(17 Sep 2019) |
Disbursements 2000-2019 (US$)(17 Sep 2019) |
% Disbursed(17 Sep 2019) |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
|
Total |
$45,006,918 |
$51,302,418 |
$45,251,819 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Support (CASHSUPP) |
$196,500 |
$221,500 |
$196,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Graduation grant (GG) |
$1,625,179 |
$1,625,179 |
$1,445,655 |
89% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health system strengthening (HSS 1) |
$438,500 |
$438,500 |
$438,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health system strengthening (HSS 2) |
$4,389,698 |
$4,389,698 |
$4,389,698 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health system strengthening (HSS 3) |
$5,400,000 |
$9,000,000 |
$4,477,923 |
83% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health system strengthening (HSS 3 - PBF) |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HepB mono (NVS) |
$82,855 |
$82,855 |
$82,855 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HPV (NVS) |
$746,500 |
$2,361,500 |
$746,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HPV Demo (NVS) |
$564,181 |
$564,181 |
$592,698 |
105% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HPV MAC (NVS) |
$2,503,500 |
$2,503,500 |
$2,499,550 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HPV MAC - Op costs (OPC) |
$134,667 |
$134,667 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immunisation services support (ISS) |
$1,431,200 |
$1,431,200 |
$1,431,200 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Injection Safety Devices (NVS) |
$172,261 |
$216,761 |
$200,101 |
116% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Injection safety support (INS) |
$255,505 |
$255,505 |
$255,505 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IPV (NVS) |
$1,775,961 |
$1,775,961 |
$1,782,002 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
JEV (NVS) |
$625,592 |
$625,592 |
$625,968 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
JEV - Operational costs (OPC) |
$1,047,500 |
$1,047,500 |
$1,047,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MR 1st and 2nd dose (NVS) |
$370,000 |
$477,000 |
$285,669 |
77% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MR 2nd dose (NVS) |
$75,090 |
$75,090 |
$75,090 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Penta (NVS) |
$9,171,966 |
$9,399,966 |
$10,077,533 |
110% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pneumo (NVS) |
$8,981,408 |
$9,657,408 |
$9,768,928 |
109% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product Switch Grant (PSG) |
$45,000 |
$45,000 |
$45,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rotavirus (NVS) |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tetra DTP-HepB (NVS) |
$3,837,114 |
$3,837,114 |
$3,837,114 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccine Introduction Grant (VIG) |
$1,136,741 |
$1,136,741 |
$950,830 |
84% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format